In a market system, society captures about 98% of the value of technological innovation, a 50:1 ratio to the innovating company's share.

The claim rests on the estimate that innovators capture about 2% of the value of their innovations and society about 98% (a ratio of about 50:1). True: credible economic research (for example, William Nordhaus's 2004 NBER paper 'Schumpeterian Profits in the American Economy') estimates that innovators capture roughly 2% of the social returns to technological innovation in a market economy, and this finding is broadly accepted as a general estimate. Mostly true: research supports a figure close to this (innovators capturing roughly 1–4%, a ratio of about 25:1 to 100:1), or the figure comes from one widely cited estimate that is not contested. Mixed: estimates vary widely, some near 2% and others far off, so the 50:1 ratio is one plausible value among several. Mostly false: the figure comes from a single study but is stated as a universal law ('inherently'), or it applies only to a narrow period, sector or measure that the claim generalises. False: research shows that innovators typically capture a large share of the value of innovation (for example, more than 10%), or no economic research supports anything near 50:1.

Set before the research began.

1. E1 The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine | Journal of Law, Medicine & Ethics | Cambridge Core Cambridge Core (Journal of Law, Medicine & Ethics)

   “Consistent with this disease-specific result, Nordhaus estimates that innovators captured only about 2.2 percent of the total surplus generated by innovation in the US nonfarm business sector from 1948 to 2001.”

2. E2 Kalil_2006-08_LINKY.indd The Hamilton Project (Brookings Institution) · December 2006

   “captured only 2.2 percent of the total value of their innovations during the period 1948–2001.”

3. E3 The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine | Journal of Law, Medicine & Ethics | Cambridge Core Cambridge Core (Journal of Law, Medicine & Ethics)

   “Philipson and Jena estimate that producers captured only about 5 percent of the nearly $1.4 trillion in social surplus generated by HIV/AIDS therapies.”

4. E4 [PDF] RATE OF RETURN TO INVESTMENT IN R&D - Frontier Economics Frontier Economics (report for the UK Department for Science, Innovation and Technology) · March 2023

   “Overall our best estimate is that the average private rate of return to R&D is at least 14% but is likely to be higher.”

E1 and E2 (independent sources) attribute to Nordhaus an estimate that innovators captured about 2.2% of the value of innovation, which matches the claimed ratio of about 50:1. That estimate covers only the US nonfarm business sector from 1948 to 2001. The only other estimate given (E3) finds producers captured about 5% of the surplus from HIV/AIDS therapies, a ratio of roughly 20:1. That figure points the same way but falls outside the 25:1–100:1 range. The evidence therefore supports a low share captured by innovators, but the exact 50:1 figure rests on one period-specific study, which the claim presents as an inherent feature of market systems; E4 measures rates of return on R&D and does not test the claimed split.